Abbott Launches New Psoriasisanswers.com Web site

AbbottAugust marks National Psoriasis Awareness Month, an opportunity to raise awareness about psoriasis, a skin disease that affects nearly 7.5 million Americans. For those living with this condition, finding information about what's happening to them can be a challenge. Abbott has launched Psoriasisanswers.com, a new educational Web site created to clear up the myths and provide facts and useful tools for people living with psoriasis.

Psoriasis is a chronic, immune disease that causes red, itchy, flaky and sometimes painful patches of skin anywhere on the body. While the exact cause is unknown, it's believed that at least 10 percent of the general population has a hereditary predisposition to the disease, though it develops in only 2-3 percent of people.

Psoriasisanswers.com offers useful tools and educational information for people living with the disease.

  • The Psoriasis Answers Widget delivers new tips and helpful facts about psoriasis every week to a personal desktop and has an interactive symptom tracker. This tracker allows patients or caregivers to privately compile detailed information about ongoing symptoms. When preparing for a visit with a dermatologist, tracker information can be printed and shared to enhance patient and doctor conversations.
  • The Psoriasis Answers Kit, which can be ordered on Psoriasisanswers.com, includes an offline version of the symptom tracker in the form of a notepad with stickers, plus Q&A Cards with tips, interesting facts and practical advice for people with the condition.

Beyond symptom tracking, Psoriasisanswers.com offers a guide to jumpstart disease discussions during office visits to ensure patients make the most of their face time with their dermatologist.

"I greatly support these types of online resources being available to psoriasis patients," says Dr. Bruce Strober, assistant professor in the Ronald O. Perelman Department of Dermatology at New York University School of Medicine. "It's very important to have information about the type and frequency of symptoms that is as accurate as possible. These tools help patients prepare for their appointments so they might have more productive and informative conversations with their physician."

Felicia Williams, who has psoriasis and is featured on Psoriasisanswers.com, urges people to be proactive about managing their condition. "It's important to take advantage of all the great resources out there like the tools on Psoriasisanswers.com. I'm thrilled to be able to share my story with others and encourage them to take control of their disease."

Psoriasis Awareness Month is sponsored by major patient advocacy organizations to encourage broader public awareness of the condition and support for people with it.

About Psoriasis
Psoriasis is a chronic, immune disease that appears on the skin. It affects an estimated 125 million people worldwide. It is a non-contagious disorder that speeds the growth cycle of skin cells and results in thick, scaly areas of skin. The most common form, called plaque psoriasis, appears as red, raised areas of skin covered with flaky white scales, which are often itchy and painful and can crack and bleed. Currently, there is no cure but treatment can help control the condition. Treatment may include topical agents, phototherapy or systemic medications taken orally or by injection or infusion. More information can be found at Psoriasisanswers.com.

About Abbott
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 83,000 people and markets its products in more than 130 countries.

Most Popular Now

GSK reaches agreement with Novartis to acquire ful…

GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has reached an agreement with Novartis for the buyout of Novartis' 36.5% stake in their Consumer Healthcare Jo...

Canadian neuroscientists say daily ibuprofen can p…

A Vancouver-based research team led by Canada's most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enou...

First proof a synthesized antibiotic is capable of…

A "game changing" new antibiotic which is capable of killing superbugs has been successfully synthesised and used to treat an infection for the first time - and could lea...

Merck partners with Medisafe to help improve medic…

Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication ...

Phase III data in The Lancet show Novartis siponim…

Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) w...

Taking a standard prostate cancer drug with food b…

By taking a high-cost drug with a low-fat meal - instead of on an empty stomach, as prescribed - prostate cancer patients could decrease their daily dose, prevent digesti...

North and south cooperation to combat tuberculosis

Tuberculosis can be cured and could be eradicated. For this to happen, however, patients have to receive the right treatment. Researchers at the Makerere University and t...

Boehringer Ingelheim and OSE Immunotherapeutics an…

Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, have announced a collaboration and excl...

New immunotherapy for lung cancer shows promise of…

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at contro...

Personalized tumor vaccine shows promise in pilot …

A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and...

Lokelma approved in the EU for the treatment of ad…

AstraZeneca today announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment...

New targeted therapy schedule could keep melanoma …

Skin melanoma, a particularly insidious cancer, accounts for the vast majority skin cancer deaths and is one of the most common cancers in people under 30. Treatment for ...